 Daniel Merrick
Concepts (327)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 41 | 2024 | 2526 | 2.880 |
Why?
| | Precancerous Conditions | 12 | 2024 | 169 | 2.450 |
Why?
| | Carcinoma, Squamous Cell | 15 | 2024 | 683 | 1.920 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 13 | 2023 | 1081 | 1.310 |
Why?
| | Adenocarcinoma | 7 | 2019 | 940 | 0.620 |
Why?
| | Bronchi | 6 | 2018 | 260 | 0.460 |
Why?
| | Chemoprevention | 4 | 2019 | 92 | 0.440 |
Why?
| | Biopsy | 8 | 2023 | 1129 | 0.410 |
Why?
| | ErbB Receptors | 6 | 2023 | 614 | 0.390 |
Why?
| | Disease Progression | 7 | 2019 | 2757 | 0.380 |
Why?
| | Carmustine | 3 | 2020 | 50 | 0.380 |
Why?
| | Biomarkers, Tumor | 8 | 2018 | 1276 | 0.370 |
Why?
| | Neovascularization, Pathologic | 5 | 2015 | 301 | 0.360 |
Why?
| | Heat-Shock Proteins | 1 | 2012 | 143 | 0.360 |
Why?
| | Bronchial Neoplasms | 2 | 2011 | 15 | 0.350 |
Why?
| | Papillomaviridae | 4 | 1996 | 125 | 0.330 |
Why?
| | Smoke | 3 | 2020 | 141 | 0.310 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 660 | 0.300 |
Why?
| | Lung Diseases | 1 | 2015 | 767 | 0.300 |
Why?
| | Keratinocytes | 4 | 1996 | 249 | 0.300 |
Why?
| | Proto-Oncogene Proteins | 3 | 2018 | 648 | 0.300 |
Why?
| | Cell Transformation, Neoplastic | 4 | 2024 | 327 | 0.300 |
Why?
| | Lung | 10 | 2025 | 4060 | 0.290 |
Why?
| | Smoking | 6 | 2019 | 1627 | 0.280 |
Why?
| | Gene Dosage | 3 | 2016 | 140 | 0.280 |
Why?
| | Formaldehyde | 2 | 2025 | 63 | 0.280 |
Why?
| | Carcinogenesis | 2 | 2020 | 217 | 0.270 |
Why?
| | Inflammation | 1 | 2018 | 2837 | 0.270 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2018 | 1396 | 0.260 |
Why?
| | B7-H1 Antigen | 2 | 2019 | 217 | 0.260 |
Why?
| | Epoprostenol | 2 | 2018 | 136 | 0.260 |
Why?
| | Iloprost | 4 | 2018 | 45 | 0.250 |
Why?
| | Carcinogens | 5 | 2018 | 125 | 0.250 |
Why?
| | Mice | 22 | 2025 | 17787 | 0.230 |
Why?
| | Humans | 53 | 2024 | 137585 | 0.230 |
Why?
| | In Situ Hybridization, Fluorescence | 3 | 2018 | 317 | 0.220 |
Why?
| | Mutation | 6 | 2023 | 3958 | 0.220 |
Why?
| | Sputum | 4 | 2019 | 311 | 0.220 |
Why?
| | Mast Cells | 1 | 2025 | 147 | 0.210 |
Why?
| | Receptor, ErbB-2 | 1 | 2006 | 341 | 0.210 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2003 | 16 | 0.210 |
Why?
| | Immunohistochemistry | 5 | 2015 | 1738 | 0.210 |
Why?
| | Chest Pain | 1 | 2003 | 91 | 0.200 |
Why?
| | Neoplasm Invasiveness | 4 | 2015 | 510 | 0.200 |
Why?
| | Desmoglein 3 | 2 | 2022 | 15 | 0.200 |
Why?
| | Lidocaine | 1 | 2022 | 42 | 0.190 |
Why?
| | Cell Proliferation | 4 | 2018 | 2475 | 0.190 |
Why?
| | Epithelial-Mesenchymal Transition | 3 | 2022 | 209 | 0.190 |
Why?
| | Gelatin | 1 | 2022 | 52 | 0.190 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 545 | 0.190 |
Why?
| | Neuropilin-1 | 1 | 2021 | 9 | 0.190 |
Why?
| | Inflammation Mediators | 1 | 2025 | 513 | 0.190 |
Why?
| | Ki-67 Antigen | 2 | 2015 | 112 | 0.180 |
Why?
| | Male | 30 | 2025 | 67762 | 0.180 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2012 | 86 | 0.180 |
Why?
| | Animals | 23 | 2025 | 36940 | 0.170 |
Why?
| | Female | 30 | 2022 | 73304 | 0.170 |
Why?
| | Middle Aged | 19 | 2020 | 33479 | 0.170 |
Why?
| | Receptor, IGF Type 1 | 2 | 2010 | 65 | 0.170 |
Why?
| | Cysts | 1 | 2021 | 113 | 0.170 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2020 | 44 | 0.160 |
Why?
| | Disease Models, Animal | 5 | 2020 | 4295 | 0.160 |
Why?
| | Aged | 13 | 2019 | 23961 | 0.160 |
Why?
| | Cell Cycle Proteins | 2 | 2018 | 617 | 0.160 |
Why?
| | Carcinoma in Situ | 1 | 2019 | 49 | 0.160 |
Why?
| | Respiratory System | 1 | 2020 | 157 | 0.160 |
Why?
| | Air Pollution | 1 | 2023 | 316 | 0.150 |
Why?
| | Pneumonia | 1 | 2025 | 639 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2023 | 801 | 0.150 |
Why?
| | Gene Expression Profiling | 2 | 2005 | 1774 | 0.150 |
Why?
| | gamma Catenin | 1 | 2018 | 13 | 0.150 |
Why?
| | Fluorescent Antibody Technique | 1 | 2019 | 390 | 0.150 |
Why?
| | Exons | 1 | 2020 | 355 | 0.150 |
Why?
| | Metaplasia | 1 | 2018 | 60 | 0.150 |
Why?
| | Bronchial Diseases | 1 | 2018 | 37 | 0.150 |
Why?
| | Mucin 5AC | 1 | 2018 | 70 | 0.140 |
Why?
| | Air Pollutants | 1 | 2023 | 430 | 0.140 |
Why?
| | Cell Cycle Checkpoints | 1 | 2018 | 98 | 0.140 |
Why?
| | MicroRNAs | 2 | 2016 | 692 | 0.140 |
Why?
| | Tobacco Smoke Pollution | 1 | 2020 | 261 | 0.140 |
Why?
| | Anticarcinogenic Agents | 1 | 2018 | 77 | 0.140 |
Why?
| | Protein Kinase Inhibitors | 3 | 2023 | 916 | 0.140 |
Why?
| | Aged, 80 and over | 7 | 2017 | 7635 | 0.130 |
Why?
| | RNA, Messenger | 5 | 2022 | 2833 | 0.130 |
Why?
| | Urethane | 4 | 2023 | 43 | 0.130 |
Why?
| | Cell Transformation, Viral | 2 | 1993 | 25 | 0.130 |
Why?
| | Frizzled Receptors | 1 | 2016 | 25 | 0.130 |
Why?
| | Antigen Presentation | 1 | 2017 | 218 | 0.130 |
Why?
| | Head and Neck Neoplasms | 1 | 2021 | 606 | 0.120 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 215 | 0.120 |
Why?
| | Myocardial Infarction | 1 | 2003 | 1046 | 0.120 |
Why?
| | Oncogenes | 1 | 2016 | 116 | 0.120 |
Why?
| | Porphyrins | 1 | 2015 | 23 | 0.120 |
Why?
| | Tomography, Spiral Computed | 1 | 2015 | 32 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2016 | 75 | 0.120 |
Why?
| | Topoisomerase Inhibitors | 1 | 2015 | 4 | 0.120 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 210 | 0.120 |
Why?
| | Smad4 Protein | 1 | 2015 | 38 | 0.120 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2018 | 434 | 0.110 |
Why?
| | Adult | 12 | 2018 | 37929 | 0.110 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2019 | 383 | 0.110 |
Why?
| | Chromosomal Instability | 1 | 2013 | 19 | 0.110 |
Why?
| | Neoplasms | 2 | 2024 | 2671 | 0.110 |
Why?
| | Macrophages, Alveolar | 2 | 2023 | 391 | 0.110 |
Why?
| | Microarray Analysis | 1 | 2013 | 117 | 0.110 |
Why?
| | Mice, Transgenic | 5 | 2018 | 2167 | 0.110 |
Why?
| | Stem Cells | 1 | 2018 | 594 | 0.100 |
Why?
| | Neoplasms, Basal Cell | 1 | 2013 | 3 | 0.100 |
Why?
| | Obesity | 1 | 2007 | 2992 | 0.100 |
Why?
| | Trachea | 1 | 2015 | 237 | 0.100 |
Why?
| | Endoscopy | 1 | 2015 | 318 | 0.100 |
Why?
| | Tretinoin | 1 | 1993 | 123 | 0.100 |
Why?
| | Interleukin-1 | 1 | 1996 | 965 | 0.100 |
Why?
| | Quinazolines | 2 | 2012 | 251 | 0.100 |
Why?
| | Piperidines | 2 | 2012 | 206 | 0.100 |
Why?
| | Prognosis | 5 | 2020 | 4030 | 0.090 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2012 | 59 | 0.090 |
Why?
| | B-Lymphocytes | 1 | 2017 | 847 | 0.090 |
Why?
| | Antigens, Differentiation | 1 | 1992 | 83 | 0.090 |
Why?
| | PTEN Phosphohydrolase | 1 | 2013 | 167 | 0.090 |
Why?
| | Cohort Studies | 3 | 2023 | 5742 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 1091 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 976 | 0.090 |
Why?
| | Cell Line | 4 | 2019 | 2847 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1692 | 0.090 |
Why?
| | Hyperplasia | 1 | 2011 | 175 | 0.090 |
Why?
| | Tissue Array Analysis | 3 | 2019 | 57 | 0.080 |
Why?
| | Early Detection of Cancer | 1 | 2015 | 447 | 0.080 |
Why?
| | Diagnosis, Differential | 3 | 2021 | 1483 | 0.080 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2012 | 234 | 0.080 |
Why?
| | Epithelium | 4 | 2018 | 313 | 0.080 |
Why?
| | Pulmonary Surgical Procedures | 1 | 2010 | 7 | 0.080 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 1040 | 0.080 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2010 | 96 | 0.080 |
Why?
| | Nuclear Proteins | 3 | 2006 | 712 | 0.080 |
Why?
| | Pulmonary Alveoli | 1 | 2012 | 405 | 0.080 |
Why?
| | Vasodilator Agents | 1 | 2011 | 331 | 0.080 |
Why?
| | Cell Polarity | 1 | 2010 | 141 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2005 | 852 | 0.080 |
Why?
| | Epithelial Cells | 4 | 2018 | 1096 | 0.070 |
Why?
| | Neoplasm Staging | 3 | 2020 | 1389 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2015 | 5131 | 0.070 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2008 | 67 | 0.070 |
Why?
| | Solitary Fibrous Tumor, Pleural | 1 | 2008 | 4 | 0.070 |
Why?
| | Osteoarthropathy, Secondary Hypertrophic | 1 | 2008 | 4 | 0.070 |
Why?
| | Echocardiography | 2 | 2003 | 642 | 0.070 |
Why?
| | Smokers | 2 | 2019 | 145 | 0.070 |
Why?
| | Prevalence | 3 | 2023 | 2734 | 0.070 |
Why?
| | Neoplasms, Experimental | 2 | 2018 | 176 | 0.070 |
Why?
| | Fibroblast Growth Factors | 1 | 2008 | 172 | 0.070 |
Why?
| | Carcinoma, Small Cell | 1 | 2008 | 172 | 0.070 |
Why?
| | Edema | 1 | 2008 | 130 | 0.070 |
Why?
| | Monocytes | 1 | 2010 | 563 | 0.070 |
Why?
| | Radiography, Thoracic | 1 | 2008 | 167 | 0.070 |
Why?
| | Genome-Wide Association Study | 1 | 2013 | 1431 | 0.070 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2607 | 0.070 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2025 | 652 | 0.060 |
Why?
| | Minichromosome Maintenance Complex Component 2 | 1 | 2006 | 4 | 0.060 |
Why?
| | Placebos | 2 | 2019 | 199 | 0.060 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 5757 | 0.060 |
Why?
| | United Kingdom | 1 | 2007 | 318 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2189 | 0.060 |
Why?
| | Hydrogels | 2 | 2023 | 678 | 0.060 |
Why?
| | Biomarkers | 4 | 2023 | 4149 | 0.060 |
Why?
| | Treatment Outcome | 5 | 2022 | 10811 | 0.060 |
Why?
| | Tumor Microenvironment | 2 | 2021 | 674 | 0.060 |
Why?
| | Cell Movement | 2 | 2025 | 967 | 0.060 |
Why?
| | Mice, Inbred A | 2 | 2020 | 49 | 0.060 |
Why?
| | Transcription Factors | 1 | 1993 | 1719 | 0.060 |
Why?
| | Hypoxia | 1 | 2012 | 1112 | 0.060 |
Why?
| | Chromosome Aberrations | 2 | 2017 | 156 | 0.060 |
Why?
| | Environment | 1 | 2007 | 358 | 0.060 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2005 | 108 | 0.060 |
Why?
| | Bronchoscopy | 2 | 2019 | 223 | 0.060 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 2018 | 267 | 0.060 |
Why?
| | Prospective Studies | 4 | 2023 | 7604 | 0.050 |
Why?
| | Global Health | 1 | 2007 | 386 | 0.050 |
Why?
| | Japan | 1 | 2003 | 115 | 0.050 |
Why?
| | Gene Knockdown Techniques | 2 | 2015 | 327 | 0.050 |
Why?
| | Keratin-5 | 1 | 2022 | 50 | 0.050 |
Why?
| | Socioeconomic Factors | 1 | 2007 | 1289 | 0.050 |
Why?
| | Aniline Compounds | 1 | 2023 | 102 | 0.050 |
Why?
| | Diagnostic Errors | 1 | 2003 | 170 | 0.050 |
Why?
| | Alveolar Epithelial Cells | 1 | 2023 | 114 | 0.050 |
Why?
| | Up-Regulation | 1 | 2005 | 843 | 0.050 |
Why?
| | Signal Transduction | 3 | 2012 | 5079 | 0.050 |
Why?
| | Dendritic Cells | 1 | 2025 | 483 | 0.050 |
Why?
| | Adaptive Immunity | 1 | 2023 | 165 | 0.050 |
Why?
| | Immunoenzyme Techniques | 2 | 2012 | 219 | 0.050 |
Why?
| | Molecular Targeted Therapy | 2 | 2018 | 411 | 0.050 |
Why?
| | Particle Size | 1 | 2023 | 394 | 0.050 |
Why?
| | Mice, Inbred BALB C | 2 | 2011 | 1272 | 0.050 |
Why?
| | Interferon-gamma | 2 | 2018 | 789 | 0.050 |
Why?
| | PPAR gamma | 1 | 2022 | 182 | 0.040 |
Why?
| | Tubulin | 1 | 2022 | 144 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2006 | 1946 | 0.040 |
Why?
| | Double-Blind Method | 2 | 2019 | 1993 | 0.040 |
Why?
| | Incidence | 2 | 2008 | 2804 | 0.040 |
Why?
| | Acute Disease | 1 | 2003 | 1007 | 0.040 |
Why?
| | Particulate Matter | 1 | 2023 | 315 | 0.040 |
Why?
| | Oximes | 1 | 2020 | 24 | 0.040 |
Why?
| | Exercise Test | 1 | 2003 | 625 | 0.040 |
Why?
| | Electrocardiography | 1 | 2003 | 629 | 0.040 |
Why?
| | Pain, Postoperative | 1 | 2022 | 265 | 0.040 |
Why?
| | Blotting, Western | 2 | 2012 | 1226 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2020 | 113 | 0.040 |
Why?
| | Rituximab | 1 | 2020 | 176 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2020 | 307 | 0.040 |
Why?
| | Cell Line, Transformed | 2 | 1996 | 145 | 0.040 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2021 | 385 | 0.040 |
Why?
| | Imidazoles | 1 | 2020 | 238 | 0.040 |
Why?
| | Remission Induction | 1 | 2019 | 288 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2011 | 2253 | 0.040 |
Why?
| | Diagnostic Imaging | 1 | 2021 | 332 | 0.040 |
Why?
| | Tobacco Smoking | 1 | 2018 | 25 | 0.040 |
Why?
| | Pyridones | 1 | 2020 | 168 | 0.040 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2018 | 68 | 0.040 |
Why?
| | RNA | 1 | 2005 | 921 | 0.040 |
Why?
| | Tricuspid Valve | 1 | 1998 | 30 | 0.040 |
Why?
| | Environmental Exposure | 1 | 2023 | 579 | 0.040 |
Why?
| | Time | 1 | 2018 | 83 | 0.040 |
Why?
| | RNA, Small Interfering | 2 | 2012 | 622 | 0.040 |
Why?
| | Ventricular Outflow Obstruction | 1 | 1998 | 43 | 0.030 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 224 | 0.030 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2018 | 155 | 0.030 |
Why?
| | Risk Factors | 3 | 2019 | 10388 | 0.030 |
Why?
| | Mass Screening | 2 | 2004 | 1287 | 0.030 |
Why?
| | Lymphocyte Count | 1 | 2017 | 148 | 0.030 |
Why?
| | Tumor Burden | 1 | 2018 | 309 | 0.030 |
Why?
| | Diabetes Mellitus | 1 | 2006 | 1040 | 0.030 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 156 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2018 | 182 | 0.030 |
Why?
| | Carcinogenicity Tests | 1 | 1996 | 10 | 0.030 |
Why?
| | Immunotherapy | 1 | 2021 | 641 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2018 | 570 | 0.030 |
Why?
| | Blotting, Northern | 1 | 1996 | 201 | 0.030 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 1996 | 49 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2016 | 4193 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 1996 | 257 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2017 | 318 | 0.030 |
Why?
| | Centrosome | 1 | 2016 | 71 | 0.030 |
Why?
| | Plasmids | 1 | 1996 | 363 | 0.030 |
Why?
| | Mitotic Index | 1 | 2015 | 25 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2019 | 442 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1325 | 0.030 |
Why?
| | Cell Differentiation | 2 | 1993 | 1991 | 0.030 |
Why?
| | Mice, Nude | 1 | 1996 | 698 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 539 | 0.030 |
Why?
| | Phenotype | 2 | 1993 | 3196 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 307 | 0.030 |
Why?
| | Loss of Heterozygosity | 1 | 2013 | 51 | 0.030 |
Why?
| | Retinoid X Receptors | 1 | 1993 | 39 | 0.030 |
Why?
| | Receptors, Retinoic Acid | 1 | 1993 | 43 | 0.030 |
Why?
| | Uterine Cervical Neoplasms | 1 | 1996 | 257 | 0.030 |
Why?
| | Organ Culture Techniques | 1 | 1993 | 156 | 0.030 |
Why?
| | Computational Biology | 1 | 2018 | 644 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2017 | 1142 | 0.030 |
Why?
| | DNA Repair | 1 | 2015 | 231 | 0.030 |
Why?
| | Drug Resistance | 1 | 1993 | 169 | 0.020 |
Why?
| | Cytosol | 1 | 1993 | 226 | 0.020 |
Why?
| | Models, Molecular | 1 | 2018 | 1570 | 0.020 |
Why?
| | Macrophages | 1 | 2020 | 1547 | 0.020 |
Why?
| | Methylcholanthrene | 1 | 2012 | 22 | 0.020 |
Why?
| | Cell Line, Tumor | 2 | 2012 | 3412 | 0.020 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2012 | 45 | 0.020 |
Why?
| | Butylated Hydroxytoluene | 1 | 2012 | 38 | 0.020 |
Why?
| | Respiratory Mucosa | 1 | 2015 | 321 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2012 | 155 | 0.020 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 1992 | 53 | 0.020 |
Why?
| | Intermediate Filament Proteins | 1 | 1992 | 57 | 0.020 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 1993 | 220 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 391 | 0.020 |
Why?
| | Administration, Topical | 1 | 2011 | 151 | 0.020 |
Why?
| | Sleep Apnea Syndromes | 1 | 2012 | 88 | 0.020 |
Why?
| | Keratins | 1 | 1992 | 173 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2012 | 139 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2013 | 341 | 0.020 |
Why?
| | United States | 2 | 2011 | 14841 | 0.020 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2012 | 243 | 0.020 |
Why?
| | Carcinoma, Large Cell | 1 | 2010 | 16 | 0.020 |
Why?
| | Administration, Oral | 1 | 2012 | 816 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 2129 | 0.020 |
Why?
| | RNA Interference | 1 | 2012 | 469 | 0.020 |
Why?
| | Cell Division | 1 | 1992 | 794 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2828 | 0.020 |
Why?
| | Aneuploidy | 1 | 2010 | 89 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 2010 | 409 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 872 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 216 | 0.020 |
Why?
| | Antioxidants | 1 | 2012 | 584 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2010 | 686 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2010 | 889 | 0.020 |
Why?
| | Survival Rate | 1 | 2011 | 1972 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2010 | 1266 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5472 | 0.020 |
Why?
| | Skin | 1 | 1991 | 752 | 0.020 |
Why?
| | Asia | 1 | 2006 | 71 | 0.020 |
Why?
| | Databases, Nucleic Acid | 1 | 2005 | 34 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 2057 | 0.020 |
Why?
| | England | 1 | 2006 | 97 | 0.020 |
Why?
| | Enzymes | 1 | 2005 | 67 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2012 | 3556 | 0.010 |
Why?
| | Age Distribution | 1 | 2006 | 392 | 0.010 |
Why?
| | Sex Distribution | 1 | 2006 | 375 | 0.010 |
Why?
| | Species Specificity | 1 | 2005 | 585 | 0.010 |
Why?
| | Cluster Analysis | 1 | 2005 | 499 | 0.010 |
Why?
| | Cytokines | 1 | 2012 | 2085 | 0.010 |
Why?
| | DNA Replication | 1 | 2005 | 238 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2005 | 767 | 0.010 |
Why?
| | Age Factors | 1 | 2011 | 3295 | 0.010 |
Why?
| | Apoptosis | 1 | 2012 | 2553 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1430 | 0.010 |
Why?
| | Models, Statistical | 1 | 2006 | 669 | 0.010 |
Why?
| | Body Weight | 1 | 2006 | 985 | 0.010 |
Why?
| | Young Adult | 1 | 2018 | 13209 | 0.010 |
Why?
| | Risk Assessment | 1 | 2010 | 3457 | 0.010 |
Why?
| | Time Factors | 1 | 2010 | 6828 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2016 | 15657 | 0.010 |
Why?
| | Echocardiography, Transesophageal | 1 | 1998 | 96 | 0.010 |
Why?
| | Infant | 1 | 2006 | 9465 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2006 | 2531 | 0.010 |
Why?
| | Culture Techniques | 1 | 1991 | 81 | 0.010 |
Why?
| | Child, Preschool | 1 | 2006 | 11074 | 0.010 |
Why?
| | Reference Values | 1 | 1991 | 816 | 0.000 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2006 | 3715 | 0.000 |
Why?
| | Adolescent | 1 | 2006 | 21513 | 0.000 |
Why?
| | Child | 1 | 2006 | 21935 | 0.000 |
Why?
|
|
Merrick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|